Free Trial
→ Is President Trump Lying To You With This? (From Colonial Metals) (Ad)
NASDAQ:NKTX

Nkarta Q3 2023 Earnings Report

Nkarta logo
$1.76 -0.06 (-3.04%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.74 -0.01 (-0.57%)
As of 05/30/2025 06:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Nkarta EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.67
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Nkarta Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nkarta Announcement Details

Quarter
Q3 2023
Date
11/9/2023
Time
N/A
Conference Call Date
Thursday, November 9, 2023
Conference Call Time
4:00PM ET

Upcoming Earnings

Nkarta's Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Monday, August 11, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Nkarta's Q3 2023 Press ReleasePress Release
(8-K)
Nkarta's Q3 2023 Quarterly reportQuarterly report
(10-Q)

Nkarta Earnings Headlines

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space
May 15, 2025 | benzinga.com
William Blair Downgrades Nkarta (NKTX)
May 15, 2025 | msn.com
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
May 31, 2025 | Colonial Metals (Ad)
Nkarta, Inc.: Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
May 15, 2025 | finanznachrichten.de
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
May 14, 2025 | globenewswire.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), Nkarta (NKTX) and Regeneron (REGN)
April 9, 2025 | markets.businessinsider.com
See More Nkarta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nkarta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nkarta and other key companies, straight to your email.

About Nkarta

Nkarta (NASDAQ:NKTX), a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

View Nkarta Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles